Otsuka

News

Otsuka joins IgAN market with Voyxact approval in US

Otsuka has claimed FDA approval for its IgAN therapy Voyxact, joining an increasingly crowded market and beating rival Vera Therapeutics to the punch.

News

App to support people with depression launches in GB

A smartphone app for depression developed by Otsuka and Click Therapeutics has been launched in Great Britain, its first European market.

News

Otsuka, Vera stake their claims to IgAN treatment

Otsuka and Vera both have new phase 3 data on drugs for kidney disease IgA nephropathy, but can they make a mark in an increasingly crowded market?

News

WhatsApp lands Moderna in hot water with PMCPA

A WhatsApp message has earned Moderna a reprimand from the UK's Prescription Medicines Code of Practice Authority (PMCPA), with Novo Nordisk, Otsuka, AstraZeneca, and Daiichi Sankyo also fo

News

Otsuka eyes early filing of IgAN drug after phase 3 readout

Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial.

News

prescription digital therapeutic on a smartphone

Otsuka, Click's depression DTx launches in the US

An FDA-approved digital therapeutic (DTx) that can be used to help people living with major depressive disorder (MDD) has been launched in the US and is available in mobile app stores.

Otsuka joins IgAN market with Voyxact approval in US

App to support people with depression launches in GB

Otsuka, Vera stake their claims to IgAN treatment

WhatsApp lands Moderna in hot water with PMCPA

Otsuka eyes early filing of IgAN drug after phase 3 readout

Otsuka, Click's depression DTx launches in the US

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Otsuka

Editor's Picks